Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines.
These NCCN Guidelines Insights highlight the important updates/changes specific to the management of metastatic breast cancer in the 2012 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer. These changes/updates include the issue of retesting of biomarkers (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2) on recurrent disease, new information regarding first-line combination endocrine therapy for metastatic disease, a new section on monitoring of patients with metastatic disease, and new information on endocrine therapy combined with an mTOR inhibitor as a subsequent therapeutic option.
Carlson, RW; Allred, DC; Anderson, BO; Burstein, HJ; Edge, SB; Farrar, WB; Forero, A; Giordano, SH; Goldstein, LJ; Gradishar, WJ; Hayes, DF; Hudis, CA; Isakoff, SJ; Ljung, B-ME; Mankoff, DA; Marcom, PK; Mayer, IA; McCormick, B; Pierce, LJ; Reed, EC; Smith, ML; Soliman, H; Somlo, G; Theriault, RL; Ward, JH; Wolff, AC; Zellars, R; Kumar, R; Shead, DA; National Comprehensive Cancer Network,
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)